Can resistance to aspirin be reversed after an additional dose?

Simple item page
dc.contributor.authorVivas Balcones, Luis David
dc.contributor.authorBernardo, Esther
dc.contributor.authorGarcía Rubira, Juan Carlos
dc.contributor.authorAzcona, Luis
dc.contributor.authorNúñez Gil, Ivan
dc.contributor.authorGonzález Ferrer, Juan José
dc.contributor.authorMacaya Miguel, Carlos
dc.contributor.authorAngiolillo, Dominick J.
dc.contributor.authorFernández Ortiz, Antonio Ignacio
dc.date.accessioned2024-02-07T12:19:16Z
dc.date.available2024-02-07T12:19:16Z
dc.date.issued2011-10-01
dc.descriptionEstudio observacional donde se evaluó en 141 pacientes con enfermedad coronaria estable en tratamiento crónico con aspirina 100mg al día si una dosis adicional reduce el porcentaje de pacientes no respondedores al tratamiento antiagregante. Tras una dosis “extra” de aspirina 100mg, el número de pacientes no respondedores a la inhibición plaquetaria con aspirina se redujo un 15% (del 50,7 al 35%).
dc.description.abstractAspirin resistance or aspirin non-responsiveness is a recently described phenomenon which has been consistently associated with an increased risk of cardiovascular events. This study was designed to determine the effects of an additional dose of 100 mg of aspirin on platelet function and proportion of aspirin non-responders using the platelet function analyzer-100 (PFA-100), in a well characterized population of stable coronary heart disease patients already on long-term aspirin treatment. Platelet function was assessed using PFA-100 in 141 patients (64.8 ± 10.1 years, 87.9% men) on long-term aspirin treatment (100 mg/day) before and 1 h after “in site” oral aspirin administration (100 mg). Prevalence of aspirin non-responders using PFA-100 was 50.7% (95% confidence interval 42.4–59). One hour after 100 mg of oral aspirin, reassessment of aspirin effects showed a prevalence of non-responders using PFA of 35.0% (95% CI 27.3–43.2) (P < 0.001 vs. pre-dose proportion). Using the PFA-100 system, reassessment of platelet function following oral administration of daily aspirin dosage significantly reduces the number of stable coronary disease patients considered to be non-responders to such treatment.
dc.description.departmentDepto. de Medicina
dc.description.facultyFac. de Medicina
dc.description.refereedTRUE
dc.description.statuspub
dc.identifier.citationVivas D, Bernardo E, García-Rubira JC, Azcona L, Núñez-Gil I, González-Ferrer JJ, et al. Can resistance to aspirin be reversed after an additional dose? J Thromb Thrombolysis. 2011;32:356-61
dc.identifier.doi10.1007/s11239-011-0596-3
dc.identifier.issn0929-5305
dc.identifier.officialurlhttps://link.springer.com/article/10.1007/s11239-011-0596-3
dc.identifier.pmid21614455
dc.identifier.relatedurlhttps://pubmed.ncbi.nlm.nih.gov/21614455/
dc.identifier.urihttps://hdl.handle.net/20.500.14352/99946
dc.issue.number3
dc.journal.titleJournal of Thrombosis and Thrombolysis
dc.language.isoeng
dc.page.final361
dc.page.initial356
dc.publisherSpringer
dc.rights.accessRightsrestricted access
dc.subject.cdu615.212
dc.subject.ucmCiencias Biomédicas
dc.subject.unesco32 Ciencias Médicas
dc.titleCan resistance to aspirin be reversed after an additional dose?
dc.typejournal article
dc.type.hasVersionVoR
dc.volume.number32
dspace.entity.typePublication
relation.isAuthorOfPublicationf6aa2c3f-13bd-44a3-8389-d7cdb310a6d2
relation.isAuthorOfPublicationb775562d-8fda-4abe-aaf2-fd622b25a3e8
relation.isAuthorOfPublication44257a01-c398-4a02-9571-1313a38b6296
relation.isAuthorOfPublication.latestForDiscoveryf6aa2c3f-13bd-44a3-8389-d7cdb310a6d2
Download
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
2011-10 J THROMB THROMBOLYSIS ASA RESISTANCE.pdf
Size:
1.87 MB
Format:
Adobe Portable Document Format
Download
Collections
Artículos